Progress of clinical research on autoimmune-associated epilepsy

doi:10.3969/j.issn.1672-6731.2023.02.004

Abstract

Abstract: Etiology of epilepsy is complex. Immune has been defined as one of the etiological groups of epilepsy. Autoimmune epilepsy attracts experts worldwide to investigate and new conceptual definitions has been proposed. Based on the pathophysiology, autoimmune epilepsy includes two entities, which are acute symptomatic seizures secondary to autoimmune encephalitis (AE) and autoimmune-associated epilepsy (AAE). We interpret the new concepts, the characteristics of extracellular and intracellular neuronal antibodies which contribute to the pathogenesis of epilepsy, and AE manifested by seizures in this review. We hope that the article helps researchers and clinicians have a better understanding of AAE and use standard terms in practical situations, thus improving diagnosis and treatment of epilepsy.

Key words: Encephalitis, Autoimmune diseases, Epilepsy, Autoantibodies, Neurons, Review

摘要： 癫痫病因复杂，免疫因素已成为癫痫的独立病因。随着对“自身免疫性癫痫”概念和发病机制的深入研究，提出“继发于自身免疫性脑炎的急性症状性发作”和“自身免疫相关性癫痫”两个概念。本文介绍“自身免疫相关性癫痫”概念进展，阐述抗神经元细胞内或细胞表面抗原抗体通过不同途径介导癫痫发作的作用机制，总结常见的以癫痫发作为主要表现的自身免疫性脑炎，以提高临床对自身免疫相关性癫痫的认识及诊断术语的规范。

关键词: 脑炎, 自身免疫疾病, 癫痫, 自身抗体, 神经元, 综述

REN Rui-qing, SHEN Kai-yuan, DING Jing, WANG Xin. Progress of clinical research on autoimmune-associated epilepsy[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2023, 23(2): 94-99.

任瑞青, 沈恺源, 丁晶, 汪昕. 自身免疫相关性癫痫临床研究进展[J]. 中国现代神经疾病杂志, 2023, 23(2): 94-99.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2023.02.004

https://journal11.magtechjournal.com/cjcnn/EN/Y2023/V23/I2/94

References

[1] Ong MS, Kohane IS, Cai T, Gorman MP, Mandl KD. Population-level evidence for an autoimmune etiology of epilepsy[J]. JAMA Neurol, 2014, 71:569-574.
[2] Steriade C. The search for autoimmune-associated epilepsy continues:are we getting closer to our target[J]? Epilepsy Curr, 2021, 21:255-257.
[3] Steriade C, Britton J, Dale RC, Gadoth A, Irani SR, Linnoila J, McKeon A, Shao XQ, Venegas V, Bien CG. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy:conceptual definitions[J]. Epilepsia, 2020, 61:1341-1351.
[4] Levite M, Goldberg H. Autoimmune epilepsy:novel multidisciplinary analysis, discoveries and insights[J]. Front Immunol, 2022, 12:762743.
[5] Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM. ILAE classification of the epilepsies:position paper of the ILAE Commission for Classification and Terminology[J]. Epilepsia, 2017, 58:512-521.
[6] Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, McCracken L, Martinez-Hernandez E, Mason WP, Kruer MC, Ritacco DG, Grisold W, Meaney BF, Alcalá C, Sillevis-Smitt P, Titulaer MJ, Balice-Gordon R, Graus F, Dalmau J. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor:a case series, characterisation of the antigen, and analysis of the effects of antibodies[J]. Lancet Neurol, 2014, 13:276-286.
[7] Zhong R, Zhang X, Chen Q, Li M, Guo X, Lin W. Acute symptomatic seizures and risk of epilepsy in autoimmune encephalitis:a retrospective cohort study[J]. Front Immunol, 2022, 13:813174.
[8] Lv RJ, Ren HT, Guan HZ, Cui T, Shao XQ. Seizure semiology:an important clinical clue to the diagnosis of autoimmune epilepsy[J]. Ann Clin Transl Neurol, 2018, 5:208-215.
[9] Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter C, Elger CE, Bien CG. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies[J]. Seizure, 2015, 30:57-63.
[10] Orsini A, Foiadelli T, Carli N, Costagliola G, Masini B, Bonuccelli A, Savasta S, Peroni D, Consolini R, Striano P. Rasmussen's encephalitis:from immune pathogenesis towards targeted-therapy[J]. Seizure, 2020, 81:76-83.
[11] Singh TD, Fugate JE, Hocker SE, Rabinstein AA. Postencephalitic epilepsy:clinical characteristics and predictors[J]. Epilepsia, 2015, 56:133-138.
[12] Carreño M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, Pimentel J, Wehner T, Mohanraj R, Uranga J, Gómez-Ibáñez A, Villanueva V, Gil F, Donaire A, Bargalló N, Rumià J, Roldán P, Setoain X, Pintor L, Boget T, Bailles E, Falip M, Aparico J, Dalmau J, Graus F. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies[J]. Epilepsy Res, 2017, 129:101-105.
[13] Gunawardane N, Fields M. Acute symptomatic seizures and provoked seizures:to treat or not to treat[J]? Curr Treat Options Neurol, 2018, 20:41.
[14] Geis C, Planagumà J, Carreño M, Graus F, Dalmau J. Autoimmune seizures and epilepsy[J]. J Clin Invest, 2019, 129:926-940.
[15] Xu X, Lu Q, Huang Y, Fan S, Zhou L, Yuan J, Yang X, Ren H, Sun D, Dai Y, Zhu H, Jiang Y, Zhu Y, Peng B, Cui L, Guan H. Anti-NMDAR encephalitis:a single-center, longitudinal study in China[J]. Neurol Neuroimmunol Neuroinflamm, 2019, 7:e633.
[16] Baumgartner T, Pitsch J, Olaciregui-Dague K, Hoppe C, Racz A, Rüber T, Becker A, von Wrede R, Surges R. Seizure underreporting in LGI1 and CASPR2 antibody encephalitis[J]. Epilepsia, 2022, 63:e100-105.
[17] Zhong R, Chen Q, Zhang X, Zhang H, Lin W. Relapses of anti-NMDAR, anti-GABABR and anti-LGI1 encephalitis:a retrospective cohort study[J]. Front Immunol, 2022, 13:918396.
[18] Karaaslan Z, Ekizoğlu E, Tektürk P, Erdağ E, Tüzün E, Bebek N, Gürses C, Baykan B. Investigation of neuronal auto-antibodies in systemic lupus erythematosus patients with epilepsy[J]. Epilepsy Res, 2017, 129:132-137.
[19] Vanli-Yavuz EN, Erdag E, Tuzun E, Ekizoglu E, Baysal-Kirac L, Ulusoy C, Peach S, Gundogdu G, Sencer S, Sencer A, Kucukali CI, Bebek N, Gurses C, Gokyigit A, Baykan B. Neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis[J]. J Neurol Neurosurg Psychiatry, 2016, 87:684-692. L, Tuzun E, Altindag E, Ekizoglu E, Kinay D,
[20] Baysal-Kirac Bilgic B, Tekturk P, Baykan B. Are there any specific EEG findings in autoimmune epilepsies[J]? Clin EEG Neurosci, 2016, 47:224-234.
[21] Errichiello L, Perruolo G, Pascarella A, Formisano P, Minetti C, Striano S, Zara F, Striano P. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy:a study on 233 patients[J]. J Neuroimmunol, 2009, 211:120-123.
[22] Miró J, Fortuny R, Juncadella M, Aiguabella M, Veciana M, Castañer S, Santurino M, Falip M. Antithyroid antibodies as a potential marker of autoimmune-mediated late onset temporal lobe epilepsy[J]. Clin Neurol Neurosurg, 2014, 121:46-50.
[23] Gillinder L, Britton J. Autoimmune-associated seizures[J]. Continuum (Minneap Minn), 2022, 28:363-398.
[24] Wu YT, Liu AH. Autoimmune factors and epilepsy[J]. Zhong Nan Da Xue Xue Bao (Yi Xue Ban), 2017, 42:1452-1457[.吴雅婷, 刘爱华. 自身免疫因素与癫痫的相关性[J]. 中南大学学报(医学版), 2017, 42:1452-1457.]
[25] Nikolopoulos D, Fanouriakis A, Boumpas DT. Update on the pathogenesis of central nervous system lupus[J]. Curr Opin Rheumatol, 2019, 31:669-677.
[26] Tanaka K, Tanaka M, Inuzuka T, Nakano R, Tsuji S. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody[J]. J Neurol Sci, 1999, 163:159-162. Biswas V, Mohanraj R. Glutamic acid
[27] Lilleker JB, decarboxylase (GAD) antibodies in epilepsy:diagnostic yield and therapeutic implications[J]. Seizure, 2014, 23:598-602.
[28] Ortega Suero G, Sola-Valls N, Escudero D, Saiz A, Graus F. Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes[J]. Neurologia (Engl Ed), 2018, 33:18-27.
[29] Bien CG, Vincent A, Barnett MH, Becker AJ, Blümcke I, Graus F, Jellinger KA, Reuss DE, Ribalta T, Schlegel J, Sutton I, Lassmann H, Bauer J. Immunopathology of autoantibody-associated encephalitides:clues for pathogenesis[J]. Brain, 2012, 135(Pt 5):1622-1638.
[30] Zhang TY, Cai MT, Zheng Y, Lai QL, Shen CH, Qiao S, Zhang YX. Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis:a review[J]. Front Immunol, 2021, 12:652820. HF, Zhang MY, Wang YP. Antibody prevalence
[31] Jia Y, Wang and immunotherapy response in Chinese patients with epilepsy and encephalopathy scores for patients with different neuronal surface antibodies[J]. Chin Med J (Engl), 2021, 134:2985-2991.
[32] Yeshokumar AK, Coughlin A, Fastman J, Psaila K, Harmon M, Randell T, Schorr EM, Han H, Hoang H, Soudant C, Jette N. Seizures in autoimmune encephalitis:a systematic review and quantitative synthesis[J]. Epilepsia, 2021, 62:397-407.
[33] Dubey D, Britton J, McKeon A, Gadoth A, Zekeridou A, Lopez Chiriboga SA, Devine M, Cerhan JH, Dunlay K, Sagen J, Ramberger M, Waters P, Irani SR, Pittock SJ. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy[J]. Ann Neurol, 2020, 87:313-323. Theorell J, Damato V, Bull J, McGlashan N,
[34] Al-Diwani A, Green E, Kienzler AK, Harrison R, Hassanali T, Campo L, Browne M, Easton A, Soleymani Majd H, Tenaka K, Iorio R, Dale RC, Harrison P, Geddes J, Quested D, Sharp D, Lee ST, Nauen DW, Makuch M, Lennox B, Fowler D, Sheerin F, Waters P, Leite MI, Handel AE, Irani SR. Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis[J]. Brain, 2022, 145:2742-2754.
[35] Feng J, Fan S, Sun Y, Ren H, Guan H, Wang J. Comprehensive B-cell immune repertoire analysis of anti-NMDAR encephalitis and anti-LGI1 encephalitis[J]. Front Immunol, 2021, 12:717598.
[36] Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, S Zagami A, Bleasel A, Somerville ER, Smith SM, Vincent A. Faciobrachial dystonic seizures precede LGI1 antibody limbic encephalitis[J]. Ann Neurol, 2011, 69:892-900.
[37] van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, van Coevorden-Hameete MH, Wirtz PW, Schreurs MW, Sillevis Smitt PA, Titulaer MJ. Anti-LGI1 encephalitis:clinical syndrome and long-term follow-up[J]. Neurology, 2016, 87:1449-1456.
[38] Muñiz-Castrillo S, Haesebaert J, Thomas L, Vogrig A, Pinto AL, Picard G, Blanc C, Do LD, Joubert B, Berzero G, Psimaras D, Alentorn A, Rogemond V, Dubois V, Ambati A, Tamouza R, Mignot E, Honnorat J. Clinical and prognostic value of immunogenetic characteristics in anti-LGI1 encephalitis[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8:e974.
[39] Rocamora R, Becerra JL, Fossas P, Gomez M, Vivanco-Hidalgo RM, Mauri JA, Molins A. Pilomotor seizures:an autonomic semiology of limbic encephalitis[J]? Seizure, 2014, 23:670-673.
[40] Teng Y, Li T, Yang Z, Su M, Ni J, Wei M, Shi J, Tian J. Clinical features and therapeutic effects of anti-leucine-rich glioma inactivated 1 encephalitis:a systematic review[J]. Front Neurol, 2022, 12:791014.
[41] Aurangzeb S, Symmonds M, Knight RK, Kennett R, Wehner T, Irani SR. LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures[J]. Seizure, 2017, 50:14-17.
[42] Gadoth A, Pittock SJ, Dubey D, McKeon A, Britton JW, Schmeling JE, Smith A, Kotsenas AL, Watson RE, Lachance DH, Flanagan EP, Lennon VA, Klein CJ. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients[J]. Ann Neurol, 2017, 82:79-92.
[43] Shan W, Yang H, Wang Q. Neuronal surface antibody-medicated autoimmune encephalitis (limbic encephalitis) in China:a multiple-center, retrospective study[J]. Front Immunol, 2021, 12:621599. Davies AM, Ng TWC, Johnson
[44] Miller TD, Chong TT, Aimola MR, Irani SR, Vincent A, Husain M, Jacob S, Maddison P, Kennard C, Gowland PA, Rosenthal CR. Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis[J]. Brain, 2017, 140:1212-1219.
[45] Escudero D, Guasp M, Ariño H, Gaig C, Martínez-Hernández E, Dalmau J, Graus F. Antibody-associated CNS syndromes without signs of inflammation in the elderly[J]. Neurology, 2017, 89:1471-1475.
[46] Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune encephalitis:a systematic analysis[J]. Front Neurol, 2019, 10:804.
[47] Planagumà J, Haselmann H, Mannara F, Petit-Pedrol M, Grünewald B, Aguilar E, Röpke L, Martín-Carcía E, Titulaer MJ, Jercog P, Graus F, Maldonado R, Geis C, Dalmau J. Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity[J]. Ann Neurol, 2016, 80:388-400.
[48] Byun JI, Lee ST, Jung KH, Sunwoo JS, Moon J, Lim JA, Lee DY, Shin YW, Kim TJ, Lee KJ, Lee WJ, Lee HS, Jun J, Kim DY, Kim MY, Kim H, Kim HJ, Suh HI, Lee Y, Kim DW, Jeong JH, Choi WC, Bae DW, Shin JW, Jeon D, Park KI, Jung KY, Chu K, Lee SK. Effect of immunotherapy on seizure outcome in patients with autoimmune encephalitis:a prospective observational registry study[J]. PLoS One, 2016, 11:e0146455.
[49] Al-Diwani A, Handel A, Townsend L, Pollak T, Leite MI, Harrison PJ, Lennox BR, Okai D, Manohar SG, Irani SR. The psychopathology of NMDAR-antibody encephalitis in adults:a systematic review and phenotypic analysis of individual patient data[J]. Lancet Psychiatry, 2019, 6:235-246.
[50] Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists:mechanisms and models[J]. Lancet Neurol, 2019, 18:1045-1057.
[51] de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, van Donselaar CA, Majoie MHJM, Neuteboom RF, Sillevis Smitt PAE, Thijs RD, Titulaer MJ. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis[J]. Neurology, 2019, 92:e2185-2196.
[52] Chanson E, Bicilli É, Lauxerois M, Kauffmann S, Chabanne R, Ducray F, Honnorat J, Clavelou P, Rosenberg S. Anti-NMDA-R encephalitis:should we consider extreme delta brush as electrical status epilepticus[J]? Neurophysiol Clin, 2016, 46:17-25.
[53] Dubey D, Singh J, Britton JW, Pittock SJ, Flanagan EP, Lennon VA, Tillema JM, Wirrell E, Shin C, So E, Cascino GD, Wingerchuk DM, Hoerth MT, Shih JJ, Nickels KC, McKeon A. Predictive models in the diagnosis and treatment of autoimmune epilepsy[J]. Epilepsia, 2017, 58:1181-1189.
[54] Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus G, Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis:an observational cohort study[J]. Lancet Neurol, 2013, 12:157-165.
[55] Zhang T, Duan Y, Ye J, Xu W, Shu N, Wang C, Li K, Liu Y. Brain MRI characteristics of patients with anti-N-methyl-D-aspartate receptor encephalitis and their associations with 2-year clinical outcome[J]. AJNR Am J Neuroradiol, 2018, 39:824-829.
[56] Wei YC, Tseng JR, Wu CL, Su FC, Weng WC, Hsu CC, Chang KH, Wu CF, Hsiao IT, Lin CP. Different FDG-PET metabolic patterns of anti-AMPAR and anti-NMDAR encephalitis:case report and literature review[J]. Brain Behav, 2020, 10:e01540.
[57] Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush:a unique EEG pattern in adults with anti-NMDA receptor encephalitis[J]. Neurology, 2012, 79:1094-1100.
[58] Gillinder L, Warren N, Hartel G, Dionisio S, O'Gorman C. EEG findings in NMDA encephalitis:a systematic review[J]. Seizure, 2019, 65:20-24.
[59] Wei W, Wei LH, Di Q. Research progress on immunological etiology of epilepsy[J]. Zhongguo Shen Jing Jing Shen Ji Bing Za Zhi, 2022, 48:121-124[.魏伟, 魏良豪, 狄晴. 癫痫免疫性病因研究进展[J]. 中国神经精神疾病杂志, 2022, 48:121-124.]
[60] Zhang YX, Pu JL, Cai MT, Tao QQ, Tian J, Shen CH, Xu YF, Zhang BR. Inflammatory markers of hemogram parameters as predictive factors for disease severity in anti-N-methyl-D-aspartate receptor encephalitis[J]. Mult Scler Relat Disord, 2022, 67:104078.
[61] Conde-Blanco E, Pascual-Diaz S, Carreño M, Muñoz-Moreno E, Pariente JC, Boget T, Manzanares I, Donaire A, Centeno M, Graus F, Bargalló N. Volumetric and shape analysis of the hippocampus in temporal lobe epilepsy with GAD65 antibodies compared with non-immune epilepsy[J]. Sci Rep, 2021, 11:10199.
[62] Dimova P, Minkin K. Case report:multisystem autoimmune and overlapping GAD65-antibody-associated neurological disorders with beneficial effect of epilepsy surgery and rituximab treatment[J]. Front Neurol, 2022, 12:756668.
[63] Langenbruch L, Bleß L, Schulte-Mecklenbeck A, Sundermann B, Brix T, Elger CE, Melzer N, Wiendl H, Meuth SG, Gross CC, Kovac S. Blood and cerebrospinal fluid immune cell profiles in patients with temporal lobe epilepsy of different etiologies[J]. Epilepsia, 2020, 61:e153-158.
[64] Falip M, Rodriguez-Bel L, Castañer S, Sala-Padró J, Miro J, Jaraba S, Casasnovas C, Morandeira F, Berdejo J, Carreño M. Hippocampus and insula are targets in epileptic patients with glutamic acid decarboxylase antibodies[J]. Front Neurol, 2019, 9:1143.
[65] Cay-Martinez KC, Hickman RA, McKhann Ii GM, Provenzano FA, Sands TT. Rasmussen encephalitis:an update[J]. Semin Neurol, 2020, 40:201-210.
[66] Tang C, Luan G, Li T. Rasmussen's encephalitis:mechanisms update and potential therapy target[J]. Ther Adv Chronic Dis, 2020, 11:2040622320971413.
[67] Nibber A, Clover L, Pettingill P, Waters P, Elger CE, Bien CG, Vincent A, Lang B. Antibodies to AMPA receptors in Rasmussen's encephalitis[J]. Eur J Paediatr Neurol, 2016, 20:222-227.
[68] Spatola M, Dalmau J. Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis[J]. Curr Opin Neurol, 2017, 30:345-353.
[69] Cao YY, Li YT, Wang JW. Autoimmune encephalitis and "autoimmune-associated epilepsy"[J]. Zhongguo Lin Chuang Yi Sheng Za Zhi, 2021, 49:646-648[.曹阳月, 李亚桐, 王佳伟. 自身免疫性脑炎与"自身免疫性癫痫"[J]. 中国临床医生杂志, 2021, 49:646-648.]
[70] Hartman AL, Cross JH. Timing of surgery in Rasmussen syndrome:is patience a virtue[J]? Epilepsy Curr, 2014, 14(1 Suppl):8-11.

Please choose a citation manager

Content to export